Introduction
The determination of time of onset is paramount in acute stroke thrombolytic treatment with intravenous recombinant tissue plasminogen activator (r-tPA), which was approved in 1996 by Food and Drug Administration; however, we cannot accurately determined the time of onset if a patient wakes with the stroke symptoms. This is called 'wake-up stroke' (WUS). 1 Approximately 20% of stroke patients present with WUS, and the odds of detecting new atrial fi brillation (AF) are three-fold higher in WUS patients. 2 Administration of intravenous r-tPA treatment in this patient group has yet to be incorporated into guidelines owing to lack of high-level evidence. Despite the recent breakthrough of endovascular thrombectomy from the DAWN and DEFUSE-3 trials, which also recruited WUS patients, endovascular treatment is not widely available and too expensive. 3, 4 In our patient, who presented with WUS, intravenous thrombolysis guided by CT perfusion fi ndings resulted in successful reperfusion despite evidence of M1 occlusion.
Case
A 42-year-old female was found to have new-onset fast AF and was observed in the high-dependency ward. She later woke-up with a stroke, and the time last seen well (TLSW) was approximately 6.5 h prior to referral to the stroke team. Clinically, her blood pressure was 160/100 mmHg with heart rate of 90 beats per minute. She suffered leftsided hemiplegia with ipsilateral facial weakness and left-sided hemi-neglect. The National Institutes of Health Stroke Scale (NIHSS) was 17. An emergency CT perfusion showed right M1 segment occlusion and the Alberta Stroke Program Early CT score (ASPECTS) was 8, with >50% penumbra. She was given r-tPA (0.9 mg/kg) at 9 h from TLSW, and the digital subtraction angiogram, with intention to treat due to presence of large vessel occlusion, showed successful reperfusion [thrombolysis in cerebral infarction (TICI) score of 3] after intravenous thrombolysis; therefore, thrombectomy was not required. The NIHSS improved to 2 upon discharge, and warfarin was started on day 12 from onset. Three months later, her Modifi ed Rankin Scale was 0. Transoesophageal echocardiogram revealed she suffered moderate-to-severe mitral stenosis with evidence of a planimetered mitral valve area of <1 cm 2 . Both mitral valve leafl ets tips were noted to be thickened, with severely restricted mobility. Dilated left atrium with good systolic function was seen. Left atrial appendage was also noted to be dilated and with reduced exit velocity. There was 1 A 42-year-old female admitted with new-onset atrial brillation had a wakeup stroke on the high-dependency unit and the time last seen well (TLSW) was 6.5 h. She suffered left-sided body weakness and her National Institutes of Health Stroke Scale (NIHSS) score was 17. An emergency CT perfusion showed right M1 segment occlusion with more than 50% penumbra. She was given recombinant tissue plasminogen activator (r-tPA) at 9 h from TLSW. An immediate diagnostic angiogram with intention to treat, owing to the presence of large vessel occlusion, showed complete reperfusion after intravenous r-tPA. She was discharged with NIHSS of 2, and at 3-month follow up her Modi ed Rankin Scale was 0. We demonstrated a successful reperfusion and excellent clinical recovery with intravenous thrombolysis in a patient who presented with a wake-up stroke with underlying valvular atrial brillation despite evidence of large vessel occlusion.
Keywords: atrial fi brillation, computed tomography perfusion, r-tPA, wake-up stroke evidence of spontaneous echo contrast over the left atrium and left atrial appendage; however, no defi nite thrombus was seen. There was no evidence of patent foramen ovale or septal defect. The patient was later scheduled for valve replacement (Figures 1-3 ).
Discussion
AF is one of the major risk factors for ischemic stroke, and is associated with a four-fold increased risk of stroke. AF patients suffer cardio-embolic stroke due to thrombus formation at the left atrial appendage. The presence of AF is associated with high 30-day and 1-year case-mortality rate and higher stroke recurrence rate within the fi rst year of follow up, as well as poorer survival after an average follow up of 45 months. 5 Therefore, stroke patients with AF have a poorer neurological outcome than patients with no AF. 6 Furthermore, the association of AF with WUS has been established, with the odds of detecting a newly diagnosed AF three-fold higher among WUS patients. 2 To date, thrombolytic treatment is considered 'off-label' for patients presenting with WUS. After publication of ECASS-3 study the r-tPA treatment window has been extended to 4.5 h from onset. 7 The advancement of radiology modalities, including MRI and CT perfusion, allow neurologists to evaluate the salvageable area called 'penumbra'. Reperfusion therapy would be able to rescue this ischemic area before it is infracted; however, most of the recently published randomised controlled trials (RCTs) utilised these modalities to assist in the decision-making prior to endovascular intervention, with the treatment window extended to within 16-24 h. 3, 4 We are still waiting for the ongoing RCT looking into the extending time window Figure 3 The time to peak, cerebral blood volume and cerebral blood flow of CT perfusion images showed more than 50% penumbra with small infarct core for thrombolytic treatment in acute ischemic stroke, which will be more feasible to a signifi cant number of patients, especially those in developing countries. 8 As in our case, the endovascular treatment is not readily available and too expensive for the patient. We believe early thrombolytic treatment is a cost-effective intervention even though there is evidence of large vessel occlusion.
Recent meta-analysis published in January 2018 showed 11% of patients who received intravenous r-tPA managed to obtain successful reperfusion without endovascular treatment. The number of patients with r-tPA-induced successful reperfusion increased to 17% if the study excluded patients who presented with tandem lesions. 9 Our patient suffered a cardio-embolic stroke due to underlying valvular AF, which explained the severity of the stroke; however, the prompt treatment provided to her resulted in a successful treatment outcome radiologically, and most importantly, immediate clinical improvement.
Conclusion
This is the fi rst case report in Malaysia related to successful reperfusion with r-tPA in WUS. CT perfusion-guided thrombolysis in WUS is safe and cost effective, especially in developing countries. Our case illustrated successful thrombolysis of acute M1 occlusion guided by CT perfusion, which resulted in immediate recovery and reduced longterm morbidity associated with cardio-embolic stroke. Larger clinical data are needed to look at the safety and effi cacy of extending the time window for thrombolysis, especially if endovascular interventions are not feasible.
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